Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Micafungin: the US perspective.

Aimee K Zaas1, William J Steinbach

  • 1Duke University Medical Center , Department of Medicine, Division of Infectious Diseases and International Health, Durham, NC 27710, USA. aimee.zaas@duke.edu

Expert Review of Anti-Infective Therapy
|May 28, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multifunctional Roles of Autophagy in Fungi.

Journal of fungi (Basel, Switzerland)·2026
Same author

Small Vessel Vasculitis Mimicking Inflammatory Bowel Disease.

ACG case reports journal·2025
Same author

Author Correction: Harnessing calcineurin-FK506-FKBP12 crystal structures from invasive fungal pathogens to develop antifungal agents.

Nature communications·2025
Same author

The Use of Artificial Intelligence in Residency Application Evaluation-A Scoping Review.

Journal of graduate medical education·2025
Same author

New Approaches and a Call to Action.

The Journal of pediatrics·2025
Same author

Structure-guided design and synthesis of C22- and C32-modified FK520 analogs with enhanced activity against human pathogenic fungi.

Proceedings of the National Academy of Sciences of the United States of America·2024

Micafungin is a new antifungal drug effective for treating candidiasis and aspergillosis. It shows promise for first-line treatment and preventing fungal infections in high-risk patients.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Invasive fungal infections (IFIs) contribute significantly to morbidity and mortality, particularly in hospital settings and immunocompromised individuals.
  • Candida species and Aspergillus species are the most prevalent causes of IFIs, with Candida bloodstream infections ranking as the fourth most common in the USA.
  • Existing antifungal drug classes include polyenes, antimetabolites, allylamines, azoles, and echinocandins.

Purpose of the Study:

  • To evaluate the safety and efficacy of micafungin, an echinocandin antifungal agent.
  • To assess micafungin's potential as a treatment for candidiasis and aspergillosis.
  • To explore micafungin's utility in prophylaxis against IFIs during neutropenia.

Main Methods:

Related Experiment Videos

  • Clinical trials were conducted in Japan, Europe, and South Africa.
  • Safety and efficacy data were collected for micafungin treatment.
  • Patient populations included those with candidiasis, aspergillosis, and neutropenia.

    • Main Results:

    • Micafungin demonstrated safety and efficacy in clinical trials for treating candidiasis and aspergillosis.
    • The drug was approved by the U.S. Food and Drug Administration in March 2005.
    • Micafungin showed potential for first-line treatment of candidiasis.

    Conclusions:

    • Micafungin is a safe and effective option for treating invasive candidiasis and aspergillosis.
    • It offers a promising therapeutic choice for candidiasis and prophylaxis in high-risk neutropenic patients.
    • The drug expands treatment options within the echinocandin class for serious fungal infections.